Efficacy and Safety of Adjunctive Perampanel in Young Children (7–46 Months) With Drug‐Resistant Epilepsy: A Real‐World Study
CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)
DOI: 10.1002/cns.70998 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 19.06.2026. Verfasst von Qiao Zeng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Minis…. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Anticonvulsants, Pyridones, Nitriles. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
To evaluate the efficacy and safety of adjunctive perampanel (PER) in young children with drug‐resistant epilepsy (DRE) aged 7–46 months, and to identify predictors of treatment response in real‐world clinical practice.
Methods
We conducted a nonrandomized, open‐label, single‐arm, self‐controlled real‐world study at the Children's Hospital of Chongqing Medical University between December 2020 and August 2024. Eighty‐seven children with DRE received PER as adjunctive therapy to existing antiseizure medications (ASMs). The primary endpoint was the responder rate (≥ 50% reduction in seizure frequency) at 3, 6, 9, and 12 months. Secondary endpoints included seizure freedom, treatment retention, and treatment‐emergent adverse events (TEAEs).
Results
Responder rates were 39.5%, 46.9%, 43.2%, and 44.4% at 3, 6, 9, and 12 months, respectively. Responder rates were 50.0% in Dravet syndrome, 50.0% in Lennox–Gastaut syndrome, and 34.8% in infantile epileptic spasms syndrome. Children with genetic etiologies had a 51.7% responder rate, including 60.0% in those with SCN1A variants. Multivariable logistic regression identified perinatal brain injury as an independent predictor of favorable response, while concomitant use of three ASMs predicted poorer outcomes. Treatment retention rates were 87.4%, 69.0%, 59.8%, and 55.2% at 3, 6, 9, and 12 months. TEAEs occurred in 23.0% of patients, most commonly somnolence (11.5%) and irritability/aggressive behavior (9.2%); 4.6% discontinued due to TEAEs.
Conclusion
Adjunctive PER demonstrated clinically meaningful efficacy and a favorable safety profile in young children with DRE, supporting its potential role as a broad‐spectrum ASM in this age group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Ch…
- Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing, China.
- Big Data Engineering Center, Children's Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Yue Hu
Zitieren
APA
Zeng, Q., Xia, X., Zheng, H., Yang, L., Jiang, L., & Hu, Y. (2026). Efficacy and Safety of Adjunctive Perampanel in Young Children (7–46 Months) With Drug‐Resistant Epilepsy: A Real‐World Study. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70998
Vancouver
Zeng Q, Xia X, Zheng H, Yang L, Jiang L, Hu Y. Efficacy and Safety of Adjunctive Perampanel in Young Children (7–46 Months) With Drug‐Resistant Epilepsy: A Real‐World Study. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70998
BibTeX
@article{Zeng2026,
author = {Zeng, Qiao and Xia, Xueqian and Zheng, Hao and Yang, Lu and Jiang, Li and Hu, Yue},
title = {Efficacy and Safety of Adjunctive Perampanel in Young Children (7–46 Months) With Drug‐Resistant Epilepsy: A Real‐World Study},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {6},
doi = {10.1002/cns.70998}
}
EUVIMED